344 related articles for article (PubMed ID: 30784671)
61. Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control: Novel Therapeutic Target.
Díaz-Guerra A; Villena-Gutiérrez R; Clemente-Moragón A; Gómez M; Oliver E; Fernández-Tocino M; Galán-Arriola C; Cádiz L; Ibáñez B
JACC CardioOncol; 2024 Apr; 6(2):217-232. PubMed ID: 38774018
[TBL] [Abstract][Full Text] [Related]
62. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
63. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
Berry G; Billingham M; Alderman E; Richardson P; Torti F; Lum B; Patek A; Martin FJ
Ann Oncol; 1998 Jul; 9(7):711-6. PubMed ID: 9739435
[TBL] [Abstract][Full Text] [Related]
64. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity.
Mornoş C; Manolis AJ; Cozma D; Kouremenos N; Zacharopoulou I; Ionac A
Hellenic J Cardiol; 2014; 55(3):235-44. PubMed ID: 24862616
[TBL] [Abstract][Full Text] [Related]
65. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients.
Laursen AH; Elming MB; Ripa RS; Hasbak P; Kjær A; Køber L; Marott JL; Thune JJ; Hutchings M
J Nucl Cardiol; 2020 Oct; 27(5):1698-1707. PubMed ID: 30298372
[TBL] [Abstract][Full Text] [Related]
66. The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index.
Ayhan SS; Özdemir K; Kayrak M; Bacaksiz A; Vatankulu MA; Eren Ö; Koc F; Duman C; Gülec H; Demir K; Ari H; Sönmez O; Gök H
Cardiol J; 2012; 19(4):363-8. PubMed ID: 22825896
[TBL] [Abstract][Full Text] [Related]
67. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
68. Outcome of serial cardiac evaluations during doxorubicin-based chemotherapy in small- to medium-sized dogs with multicentric lymphoma.
Tang YS; Wang SL
Vet J; 2024 Jun; 305():106134. PubMed ID: 38750812
[TBL] [Abstract][Full Text] [Related]
69. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
Blank N; Laskov I; Kessous R; Kogan L; Lau S; Sebag IA; Gotlieb WH; Rudski L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):737-743. PubMed ID: 28801766
[TBL] [Abstract][Full Text] [Related]
70. Dietary omega-3 supplementation exacerbates left ventricular dysfunction in an ovine model of anthracycline-induced cardiotoxicity.
Carbone A; Psaltis PJ; Nelson AJ; Metcalf R; Richardson JD; Weightman M; Thomas A; Finnie JW; Young GD; Worthley SG
J Card Fail; 2012 Jun; 18(6):502-11. PubMed ID: 22633309
[TBL] [Abstract][Full Text] [Related]
71. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
Katamadze NA; Lartsuliani KP; Kiknadze MP
Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
[TBL] [Abstract][Full Text] [Related]
72. The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.
Jafari F; Safaei AM; Hosseini L; Asadian S; Kamangar TM; Zadehbagheri F; Rezaeian N
Heart Fail Rev; 2021 May; 26(3):679-697. PubMed ID: 33029698
[TBL] [Abstract][Full Text] [Related]
73. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping.
Ntusi NAB; Piechnik SK; Francis JM; Ferreira VM; Matthews PM; Robson MD; Wordsworth PB; Neubauer S; Karamitsos TD
JACC Cardiovasc Imaging; 2015 May; 8(5):526-536. PubMed ID: 25890584
[TBL] [Abstract][Full Text] [Related]
74. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of a shortened cardiac MRI protocol for left ventricular examinations: diagnostic performance of T1-mapping and myocardial function analysis.
Nadjiri J; Zaschka AL; Straeter AS; Sauter A; Englmaier M; Weis F; Laugwitz KL; Rummeny EJ; Pfeiffer D; Rasper M
BMC Med Imaging; 2019 Jul; 19(1):57. PubMed ID: 31340756
[TBL] [Abstract][Full Text] [Related]
76. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T].
Wang W; Kang Y; Shu XH; Shen XD; He B
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290
[No Abstract] [Full Text] [Related]
77. Modelling cardiac mechanics in doxorubicin-induced cardiotoxicity following childhood acute lymphoblastic leukemia using a combination of cardiac magnetic resonance imaging, cardiopulmonary exercise testing and the CircAdapt model.
Artz T; Caru M; Curnier D; Abasq M; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Biomech; 2023 Jun; 154():111616. PubMed ID: 37207545
[TBL] [Abstract][Full Text] [Related]
78. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
79. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
80. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction.
Rommel KP; von Roeder M; Latuscynski K; Oberueck C; Blazek S; Fengler K; Besler C; Sandri M; Lücke C; Gutberlet M; Linke A; Schuler G; Lurz P
J Am Coll Cardiol; 2016 Apr; 67(15):1815-1825. PubMed ID: 27081022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
